quincetx.com Open in urlscan Pro
35.166.243.108  Public Scan

Form analysis
1 forms found in the DOM

GET https://quincetx.com/

<form role="search" action="https://quincetx.com/" method="GET">
  <input type="text" name="s" value="" aria-label="Search" placeholder="Search">
  <span>Hit enter to search or ESC to close</span>
</form>

Text Content

Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
 * Team
 * Pipeline
 * Science
 * Patients
 * News
 * Investors
 * Careers
 * Contact




UNLOCKING THE POWER OF A PATIENT’S OWN BIOLOGY FOR THE TREATMENT OF RARE
DISEASES


QUINCE THERAPEUTICS, INC. IS A LATE-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO
UNLOCKING THE POWER OF A PATIENT’S OWN BIOLOGY FOR THE TREATMENT OF RARE
DISEASES. OUR PHASE 3 LEAD ASSET, ERYDEX, FOR THE TREATMENT OF THE RARE
PEDIATRIC NEURODEGENERATIVE DISEASE ATAXIA-TELANGIECTASIA (A-T) IS THE FIRST
PRODUCT IN DEVELOPMENT THAT LEVERAGES OUR PROPRIETARY AUTOLOGOUS INTRACELLULAR
DRUG ENCAPSULATION, OR AIDE, TECHNOLOGY PLATFORM, WHICH IS A NOVEL DRUG/DEVICE
COMBINATION THAT USES AN AUTOMATED PROCESS DESIGNED TO ENCAPSULATE A DRUG INTO
THE PATIENT’S OWN RED BLOOD CELLS.


ENROLLING PIVOTAL PHASE 3 NEAT CLINICAL TRIAL OF ERYDEX IN PATIENTS WITH A-T

Our strategic focus is to complete the pivotal Phase 3 clinical trial of EryDex,
called NEAT (Neurologic Effects of EryDex on Subjects with A-T), to evaluate the
safety and efficacy of EryDex for the treatment of Ataxia-Telangiectasia (A-T).
A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency
disorder with currently no approved therapeutic treatments in any global market
for this rare pediatric disease.

Quince has dosed the first patient and is actively enrolling participants for
our global Phase 3 NEAT study. Patients with A-T interested in participating can
learn more about the NEAT study criteria and locations by visiting
Clinicaltrials.gov here and Clinical Trials Information System here.

The U.S. Food and Drug Administration granted Fast Track designation for our
EryDex System for the treatment of patients with A-T, underscoring the high
unmet medical need as there are currently no approved therapeutic treatments for
A-T.

Our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology
platform is an innovative drug/device combination that uses an automated process
to encapsulate a drug into a patient’s own red blood cells. Red blood cells have
several characteristics that make them a potentially ideal vehicle for drug
delivery, including potentially better tolerability, enhanced tissue
distribution, reduced immunogenicity, and prolongation of circulating half-life.
Our AIDE technology is designed to harness many of these benefits to allow for
new and improved therapeutic options for patients living with high unmet medical
needs.

EryDex is the first product in development that leverages our AIDE technology
and is composed of dexamethasone sodium phosphate (DSP) encapsulated in
autologous red blood cells targeted for the treatment of patients with A-T. DSP
is a corticosteroid well known for its potent anti-inflammatory properties, as
well as its dose-limiting toxicity due to adrenal suppression. EryDex is
designed to provide the efficacy of corticosteroids and to reduce or eliminate
the significant adverse effects that accompany chronic corticosteroid treatment.

AIDE Technology PlatformEryDex Phase 3 NEAT Clinical Trial


QUINCE IN THE NEWS

13/11/2024


QUINCE THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2024
FINANCIAL RESULTS

Read News Release

12/11/2024


QUINCE THERAPEUTICS PRESENTS DATA FROM PRIOR PHASE 3 ATTEST CLINICAL TRIAL AT
2024 INTERNATIONAL CONGRESS FOR ATAXIA RESEARCH

Read News Release

11/11/2024


QUINCE THERAPEUTICS PRESENTS SAFETY DATA FROM PRIOR PHASE 3 ATTEST CLINICAL
TRIAL AT 53RD CHILD NEUROLOGY SOCIETY ANNUAL MEETING

Read News Release

More News
Sign up for email alerts
Reserved Area
 * twitter
 * facebook
 * linkedin
 * youtube

Please note our Privacy Policy and Terms of Use. © 2024 Quince.

 * Team
 * Pipeline
 * Science
 * Patients
 * News
 * Investors
 * Careers
 * Contact

 * 
 * 
 * 
 * 


Close Menu
Want to learn more about Quince’s lead indication Ataxia-Telangiectasia?
Visit our Patients page here to meet Shane and his family and experience the A-T
journey through their perspective.


Want to learn more about Quince’s lead indication Ataxia-Telangiectasia?
Visit our Patients page here to meet Shane and his family and experience the A-T
journey through their perspective.